Slideshow

Antipsychotic Augmentation vs Monotherapy in Schizophrenia

Author(s):

Brian Miller, MD, PhD, MPH

To augment or not to augment? That is the question.

View the slides in PDF format. Also see: Antipsychotics and Breast Cancer Risk.

Related Videos
Have A Nice Day Photo/AdobeStock
Tasphong/AdobeStock
Andrey/AdobeStock
Andrii Yalaanskyi/AdobeStock
Tierney/AdobeStock
VectorStory/AdobeStock
Julyuela/AdobeStock
Venusvi/AdobeStock
RolfImages/AdobeStock
CravenA/AdobeStock
Related Content
Justlight/AdobeStock
March 13th 2025

Lindus Health and Sooma Medical Launch Phase 3 Trial for Transcranial Direct Current Stimulation in Treating MDD

Megan McSweeney
Here's to a Psychedelic Revolution
April 9th 2022

Here's to a Psychedelic Revolution

Amir Inamdar MBBS, DNB (Psych), MFPM
schizophrenia
March 10th 2025

How the Study of Muscarinic Receptors Is Transforming Schizophrenia Treatment

Khutaija Noor, MBBS, FCR
Blue Light Blockers: A Behavior Therapy for Mania
October 7th 2021

Blue Light Blockers: A Behavior Therapy for Mania

Chris Aiken, MD Kellie Newsome, PMH-NP
postpartum
March 7th 2025

Tragic or Treated: Why We Cannot Miss Postpartum Psychosis

Meghan Cliffel Susan Hatters Friedman, MD, MSt, DFAPA
yana136/AdobeStock
March 5th 2025

Ketamine, TMS Show Promise in Treatment-Resistant Depression in Older Adults

Megan McSweeney
© 2025 MJH Life Sciences

All rights reserved.